Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
May 9 BMY Q1 2024 Editas Medicine Inc Earnings Call
May 9 VRTX Dow Jones Futures: S&P 500 Holds, Toast Leads 5 New Buys; Robinhood, Arm Are Earnings Movers Late
May 8 SCYX SCYNEXIS GAAP EPS of $0.01 beats by $0.20, revenue of $1.37M beats by $1.07M
May 8 SCYX SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8 IONS Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
May 8 VRTX A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
May 8 VRTX Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets
May 8 SCYX Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years
May 8 IONS Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
May 8 VRTX Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
May 8 VRTX Vertex Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
May 8 ABBV QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
May 8 IONS Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 BMY Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
May 8 NNVC A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
May 8 VRTX 5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
May 8 IONS Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
May 8 IONS Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
May 7 ABBV Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags